Abeona Therapeutics Q2 net income beats estimates on PRV sale, sees profitability in H1 2026

Overview

• Abeona Q2 net income of $108.8 mln beats analyst expectations, per LSEG data

• Adjusted EPS of $1.71 beats estimates, driven sale of Rare Pediatric Disease priority review voucher (PRVsale)

• ZEVASKYN U.S. launch on track and first patient treatment expected in Q3

• Says with Abeona transitioning into a commercial organization, some manufacturing and development costs reclassified from R&D expense to inventory or SG&A expenses.

Outlook

• Abeona expects first ZEVASKYN treatment in Q3

• Company anticipates profitability in 1H 2026

• Company plans to scale ZEVASKYN supply to 10 patients/month by mid-2026

Result Drivers

• FDA APPROVAL - ZEVASKYN received FDA approval in April 2025 for treating RDEB, marking a key milestone for Abeona

• STRONG PATIENT INTEREST - High demand for ZEVASKYN with multiple patients identified and progressing towards treatment, per CEO Vish Seshadri

• INSURANCE COVERAGE - Positive insurance coverage established with major national and regional payers, facilitating broad patient access

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Abeona Therapeutics Inc is $20.00, about 67.2% above its August 13 closing price of $6.56

Press Release: ID:nGNX2Lz1Sj